Expression and functional significance of HtrA1 loss in endometrial cancer

Sally A. Mullany, Mehdi Moslemi-Kebria, Ramandeep Rattan, Ashwani Khurana, Amy Clayton, Takayo Ota, Andrea Mariani, Karl C. Podratz, Jeremy Chien, Vijayalakshmi Shridhar

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines. Experimental design: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones. Results: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016). Conclusions: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors.

Original languageEnglish (US)
Pages (from-to)427-436
Number of pages10
JournalClinical Cancer Research
Volume17
Issue number3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Endometrial Neoplasms
Cell Line
Neoplasms
Down-Regulation
Western Blotting
Neoplasm Metastasis
Lung
Serine Proteases
Tumor Cell Line
Heterografts
Cell Movement
Peptide Hydrolases
Research Design
Clone Cells
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mullany, S. A., Moslemi-Kebria, M., Rattan, R., Khurana, A., Clayton, A., Ota, T., ... Shridhar, V. (2011). Expression and functional significance of HtrA1 loss in endometrial cancer. Clinical Cancer Research, 17(3), 427-436. https://doi.org/10.1158/1078-0432.CCR-09-3069

Expression and functional significance of HtrA1 loss in endometrial cancer. / Mullany, Sally A.; Moslemi-Kebria, Mehdi; Rattan, Ramandeep; Khurana, Ashwani; Clayton, Amy; Ota, Takayo; Mariani, Andrea; Podratz, Karl C.; Chien, Jeremy; Shridhar, Vijayalakshmi.

In: Clinical Cancer Research, Vol. 17, No. 3, 01.02.2011, p. 427-436.

Research output: Contribution to journalArticle

Mullany, SA, Moslemi-Kebria, M, Rattan, R, Khurana, A, Clayton, A, Ota, T, Mariani, A, Podratz, KC, Chien, J & Shridhar, V 2011, 'Expression and functional significance of HtrA1 loss in endometrial cancer', Clinical Cancer Research, vol. 17, no. 3, pp. 427-436. https://doi.org/10.1158/1078-0432.CCR-09-3069
Mullany SA, Moslemi-Kebria M, Rattan R, Khurana A, Clayton A, Ota T et al. Expression and functional significance of HtrA1 loss in endometrial cancer. Clinical Cancer Research. 2011 Feb 1;17(3):427-436. https://doi.org/10.1158/1078-0432.CCR-09-3069
Mullany, Sally A. ; Moslemi-Kebria, Mehdi ; Rattan, Ramandeep ; Khurana, Ashwani ; Clayton, Amy ; Ota, Takayo ; Mariani, Andrea ; Podratz, Karl C. ; Chien, Jeremy ; Shridhar, Vijayalakshmi. / Expression and functional significance of HtrA1 loss in endometrial cancer. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 3. pp. 427-436.
@article{16119967d02c4b839d252982f8668a90,
title = "Expression and functional significance of HtrA1 loss in endometrial cancer",
abstract = "Purpose: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines. Experimental design: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones. Results: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57{\%} (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016). Conclusions: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors.",
author = "Mullany, {Sally A.} and Mehdi Moslemi-Kebria and Ramandeep Rattan and Ashwani Khurana and Amy Clayton and Takayo Ota and Andrea Mariani and Podratz, {Karl C.} and Jeremy Chien and Vijayalakshmi Shridhar",
year = "2011",
month = "2",
day = "1",
doi = "10.1158/1078-0432.CCR-09-3069",
language = "English (US)",
volume = "17",
pages = "427--436",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Expression and functional significance of HtrA1 loss in endometrial cancer

AU - Mullany, Sally A.

AU - Moslemi-Kebria, Mehdi

AU - Rattan, Ramandeep

AU - Khurana, Ashwani

AU - Clayton, Amy

AU - Ota, Takayo

AU - Mariani, Andrea

AU - Podratz, Karl C.

AU - Chien, Jeremy

AU - Shridhar, Vijayalakshmi

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Purpose: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines. Experimental design: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones. Results: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016). Conclusions: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors.

AB - Purpose: The purpose of this study was to determine if loss of serine protease HtrA1 in endometrial cancer will promote the invasive potential of EC cell lines. Experimental design: Western blot analysis and immunohistochemistry methods were used to determine HtrA1 expression in EC cell lines and primary tumors, respectively. Migration, invasion assays and in vivo xenograft experiment were performed to compare the extent of metastasis between HtrA1 expressing and HtrA1 knocked down clones. Results: Western blot analysis of HtrA1 in 13 EC cell lines revealed complete loss of HtrA1 expression in all seven papillary serous EC cell lines. Downregulation of HtrA1 in Hec1A and Hec1B cell lines resulted in a three- to fourfold increase in the invasive potential. Exogenous expression of HtrA1 in Ark1 and Ark2 cells resulted in three- to fourfold decrease in both invasive and migration potential of these cells. There was an increased rate of metastasis to the lungs associated with HtrA1 downregulation in Hec1B cells compared to control cells with endogenous HtrA1 expression. Enhanced expression of HtrA1 in Ark2 cells resulted in significantly less tumor nodules metastasizing to the lungs compared to parental or protease deficient (SA mutant) Ark2 cells. Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression. The association of low HtrA1 expression with high-grade endometrioid tumors was statistically significant (P = 0.016). Conclusions: Collectively, these data indicate loss of HtrA1 may contribute to the aggressiveness and metastatic ability of endometrial tumors.

UR - http://www.scopus.com/inward/record.url?scp=79551719110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551719110&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-3069

DO - 10.1158/1078-0432.CCR-09-3069

M3 - Article

C2 - 21098697

AN - SCOPUS:79551719110

VL - 17

SP - 427

EP - 436

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -